Bristol Myers Squibb’s Zeposia shows promising results in phase 3 True North trial for ulcerative colitis treatment
Bristol Myers Squibb (BMS) has reported significant success in its phase 3 True North clinical trial, evaluating the efficacy of Zeposia (ozanimod) as an oral ... Read More
Bristol-Myers Squibb to acquire Celgene in $74bn pharma megadeal
Bristol-Myers Squibb has reached a definitive agreement to acquire Celgene Corporation in a monumental cash-and-stock deal worth approximately $74 billion. This acquisition will merge two ... Read More